A Phase 1b Trial of Adaptive Stereotactic Body Radiotherapy in Combination With Durvalumab (MEDI4736), Platinum, and Etoposide in Extensive Stage Small Cell Lung Cancer

NCT05403723 Phase 1 SUSPENDED

This is trial studying the safety of adaptive stereotactic body radiotherapy (SBRT) combined with durvalumab immunotherapy, platinum chemotherapy, and etoposide chemotherapy in platinum refractory extensive stage small cell lung cancer (SCLC).

Details

Lead sponsor	University of Maryland, Baltimore
Phase	Phase 1
Status	SUSPENDED
Enrolment	50
Start date	2026-06-30
Completion	2027-08

Conditions

• Extensive-stage Small-cell Lung Cancer

Interventions

• Durvalumab 50 MG/1 ML Intravenous Solution
• Etoposide Injection
• Cisplatin
• Carboplatin
• Stereotactic Body Radiotherapy

Primary outcomes

• Incidence of treatment-related adverse events (AEs) — Up to 2.5 years
  Number of patients that experience Adverse Events (AEs) assessed according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Adverse Events will be described by Type, Category, including only most severe Grade experienced by a single patient.

Countries

United States